Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)

被引：0

作者：

Liu, Xiufeng ^{[1
]}

Lu, Yinying ^{[2
]}

Zhou, Weiping ^{[3
]}

Peng, Tao ^{[4
]}

Zhou, Jie ^{[5
]}

Bi, Huaqiang ^{[6
]}

Xia, Feng ^{[6
]}

Chen, Xiaoping ^{[7
]}

机构：

[1] Jinling Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Peoples R China

[2] Peoples Liberat Army Gen Hosp, Comprehens Liver Canc Ctr, Med Ctr 5, Beijing, Peoples R China

[3] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 3, Shanghai, Peoples R China

[4] Guangxi Med Univ, Affiliated Hosp 1, Hepatobiliary Surg Dept, Nanning, Peoples R China

[5] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Div Hepatobiliopancreat Surg & Liver Transplantat, Guangzhou, Peoples R China

[6] Army Med Univ, Hosp 1, Dept Hepatobiliary Surg, Chongqing, Peoples R China

[7] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan, Peoples R China

来源：

LIVER CANCER | 2024年 / 13卷 / 04期

关键词：

Hepatocellular carcinoma; Immunotherapy; Combination therapy; Immune checkpoint inhibitors; Multidisciplinary team; Consensus; TENOFOVIR DISOPROXIL FUMARATE; OPEN-LABEL; DOUBLE-BLIND; CONVERSION THERAPY; SINTILIMAB PLUS; SORAFENIB; PHASE-3; IMMUNOTHERAPY; ATEZOLIZUMAB; MULTICENTER;

D O I：

10.1159/000535496

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. Summary: To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 edition. Key Messages: This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.

引用

页码：355 / 375

页数：21